Rhythm Pharmaceuticals (MEX:RYTM) Shares Outstanding (EOP): 68 Mil (As of Mar. 2026)


MEX:RYTM Rhythm Pharmaceuticals Inc MEX:RYTM
56 GF Score
Price MXN1,866.76
GF Value MXN1,863.73
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Shares Outstanding (EOP)?

Rhythm Pharmaceuticals MEX:RYTM 56 Shares Outstanding (EOP) is 68 Mil as of Mar. 2026. GuruFocus rates MEX:RYTM with a GF Score™ of 56/100 and a GF Value™ of MXN1,863.73. The stock has 3 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Rhythm Pharmaceuticals's shares outstanding for the quarter that ended in Mar. 2026 was 68 Mil.

Rhythm Pharmaceuticals's quarterly shares outstanding increased from Dec. 2025 (67 Mil) to Mar. 2026 (68 Mil). It means Rhythm Pharmaceuticals issued new shares from Dec. 2025 to Mar. 2026 .

Rhythm Pharmaceuticals's annual shares outstanding increased from Dec. 2024 (62 Mil) to Dec. 2025 (67 Mil). It means Rhythm Pharmaceuticals issued new shares from Dec. 2024 to Dec. 2025 .


Rhythm Pharmaceuticals  (MEX:RYTM) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Rhythm Pharmaceuticals Shares Outstanding (EOP) Related Terms


Rhythm Pharmaceuticals Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Rhythm Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Pharmaceuticals Shares Outstanding (EOP) Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.28 56.61 59.43 62.39 67.21

Rhythm Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.50 63.91 66.68 67.21 68.45

MEX:RYTM vs MIRM, SYRE, PTGX: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Rhythm Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Pharmaceuticals Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's Shares Outstanding (EOP) falls into.


MEX:RYTM
56GF Score
Rhythm Pharmaceuticals Inc MEX:RYTM
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 68 Mil mean?
Rhythm Pharmaceuticals (MEX:RYTM) has a Shares Outstanding (EOP) of 68 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Rhythm Pharmaceuticals and its competitors.
Is Rhythm Pharmaceuticals' Shares Outstanding (EOP) too high?
Rhythm Pharmaceuticals' current Shares Outstanding (EOP) is 68 Mil. Overall, Rhythm Pharmaceuticals has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Shares Outstanding (EOP) compare to MIRM and SYRE?
Rhythm Pharmaceuticals' Shares Outstanding (EOP) of 68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Rhythm Pharmaceuticals and its competitors. Rhythm Pharmaceuticals's current Shares Outstanding (EOP) is 68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Rhythm Pharmaceuticals (MEX:RYTM) has a current Shares Outstanding (EOP) of 68 Mil. The stock's GF Value™ is MXN1,863.73, compared to a current price of MXN1,866.76 — trading 0.2% above its estimated fair value. The current Shares Outstanding (EOP) is 68 Mil. Rhythm Pharmaceuticals' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Rhythm Pharmaceuticals (MEX:RYTM), the current Shares Outstanding (EOP) is 68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rhythm Pharmaceuticals (MEX:RYTM) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,866.76 is trading 0.2% above its estimated GF Value™ of MXN1,863.73.

Key valuation signals for MEX:RYTM:

  • Shares Outstanding (EOP): 68 Mil
  • GF Value™: MXN1,863.73 vs. price of MXN1,866.76 (0.2% above fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the MEX:RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rhythm Pharmaceuticals Business Description

Other Exchanges RYTM:USA1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
56GF Score

Get the complete analysis for MEX:RYTM

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,866.76
Price
MXN1,863.73
GF Value